ClinicalTrials.gg
RecruitingNCT07347665Updated Jul 17, 2026

Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery

An interventional study of Endovascular therapy in Endovascular Therapy, Acute Ischemic Stroke and Acute Ischemic Stroke (AIS) Related to a Distal Occlusion, sponsored by Hyogo Medical University. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Hyogo Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.

Planned enrollment
22nd of 35
200 · median 270
Started
2025
with 2 others
No phase
10 of 43
1 open now
Primary completion
2028-03
later than 6 of 10 live
Registered
41st of 43
by date
Lead sponsor
5 of 43
Hyogo Medical University

Among the 43 studies in Ischemic Stroke with a site in Japan, this one is the 22nd largest by planned enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 41st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ischemic Stroke with a site in Japan, or all of them as a file.
02

Study summary

RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.

03

Conditions studied

  • Endovascular Therapy
  • Acute Ischemic Stroke
  • Acute Ischemic Stroke (AIS) Related to a Distal Occlusion

Browse trials for

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute cerebral infarction
  2. Aged 18-84 years
  3. NIHSS score at admission ≥ 8
  4. Prestroke mRS scores of 0-1 (able to carry out all usual activities)
  5. Occlusion of the M2 segment of MCA on digital subtraction angiography
  6. ASPECTS ≥ 8 or DWI-ASPECTS ≥ 8
  7. Ineligible or failed intravenous tPA (no recanalization within 30 min after injection)
  8. Randomization can be completed within 24 h from the last known well time
  9. EVT can be initiated within 30 min from randomization.
  10. The patient or their legally authorized representative has signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Occlusion of the anterior temporal artery, duplicate M1, or accessory M1
  2. Occlusion of multiple major intracranial arteries
  3. Difficulty in endovascular access due to tortuous vascular anatomy
  4. Significant mass effect with midline shift on CT (or MRI)
  5. Known allergy (more severe than skin rash) to contrast agents
  6. Evidence of acute intracranial hemorrhage on CT (or MRI)
  7. Pregnant or potentially pregnant
  8. Clinical evidence of chronic occlusion
  9. High risk of hemorrhage ( \< 40,000/ul, > 50 sec or PT-INR > 3.0)
  10. Participating in any other therapeutic trial
  11. Judgment of the investigator to be non-compliant or uncooperative during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Medical therapy with endovascular therapy

    Procedure: Endovascular therapy

  • No intervention
    Medical therapy alone

Interventions

  • ProcedureEndovascular therapy

    Endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.

06

What researchers measure

Primary outcomes

  1. Achievement of modified Rankin Scale (mRS; range, 0-6; higher scores reflect worse functional outcome) scores of 0-2

    modified Rankin Scale (mRS) is an ordinal scale ranging from 0 (no symptoms) to 6 (death) measuring the degree of disability or dependence in everyday life.

    Time frame: 90 days after randomization

Secondary outcomes

  1. Achievement of modified Rankin Scale (mRS; range, 0-6; higher scores reflect worse functional outcome) scores of 0-1

    Time frame: 90 days after randomization

  2. modified Rankin Scale (mRS; range, 0-6; higher scores reflect worse functional outcome) shift analysis

    Time frame: 90 days after randomization

  3. National Institutes of Health Stroke Scale (NIHSS; range, 0-42; higher scores indicate more severe neurological impairment) improvement of 8 points or more

    Time frame: 48 hours after randomization

  4. Health-related quality of life assessed using the EuroQol 5-Dimension 3-Level (EQ-5D-3L; range, 0-1.0; higher scores indicating better health-related quality of life)

    Time frame: 90 days after randomization

  5. Symptomatic intracranial hemorrhage

    Time frame: 48 hours after randomization

  6. Any intracranial hemorrhage

    Time frame: 48 hours after randomization

  7. All cause death

    Time frame: 90 days after randomization

  8. Recurrence of cerebral infarction

    Time frame: 90 days after randomization

  9. Decompressive craniectomy

    Time frame: 7 days after randomization

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2028, 27 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 27 months is close to that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 16, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2030
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07347665
Lead sponsor
Hyogo Medical University
Responsible party
Kazutaka Uchida (Associate Professor (Stroke Center), Hyogo Medical University) — Principal investigator
First posted
Jan 16, 2026
Start date
Dec 1, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Jul 17, 2026

Study contacts

Kazutaka Uchida, MD, PhD
Contact
fu-sakakibara@hyo-med.ac.jp
81+798-45-6458

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion